Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma.

Cancer - 15 Nov 2015

Buchbinder Elizabeth I, Sosman Jeffrey A, Lawrence Donald P, McDermott David F, Ramaiya Nikhil H, Van den Abbeele Annick D, Linette Gerald P, Giobbie-Hurder Anita, Hodi F Stephen

Abstract excerpt

BACKGROUND: Patients with mucosal and acral melanomas have limited treatment options and a poor prognosis. Mutations of the KIT oncogene in these melanoma subtypes provide a potential therapeutic target. METHODS: A multicenter phase 2 trial of sunitinib was conducted in patients with unresectable stage III or IV melanoma of a mucosal or acral primary origin. Patients were treated in 2 cohorts: cohort A received...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Indoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Mucous Membrane

Share to Proto-Oncogene Proteins c-kit

Share to Pyrroles

Share to Skin Neoplasms

Share to Sunitinib

Source

Identifiers

PMID: 26264378
DOI: 10.1002/cncr.29622

Genes

KIT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma.PMID 26264378Read ↗

Treatment of acral and mucosal melanoma: Current and emerging targeted therapies.Semantic proximity Read ↗

A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607).Semantic proximity Read ↗

KIT as a therapeutic target in metastatic melanoma.Semantic proximity Read ↗

c-Kit inhibitors for unresectable or metastatic mucosal, acral or chronically sun-damaged melanoma: a systematic review and one-arm meta-analysis.Semantic proximity Read ↗

Management of Acral and Mucosal Melanoma: Medical Oncology Perspective.Semantic proximity Read ↗

Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions.Semantic proximity Read ↗

Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.Semantic proximity Read ↗

Another Option in Our KIT of Effective Therapies for Advanced MelanomaSemantic proximity Read ↗

Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT.Semantic proximity Read ↗

Sunitinib therapy for melanoma patients with KIT mutations.Semantic proximity Read ↗

The clinical significance of KIT mutations in melanoma: a meta-analysis.Semantic proximity Read ↗

Advances in targeted therapy for melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.